WO2014004863A3 - Compounds, compositions, and therapeutic uses thereof - Google Patents

Compounds, compositions, and therapeutic uses thereof Download PDF

Info

Publication number
WO2014004863A3
WO2014004863A3 PCT/US2013/048243 US2013048243W WO2014004863A3 WO 2014004863 A3 WO2014004863 A3 WO 2014004863A3 US 2013048243 W US2013048243 W US 2013048243W WO 2014004863 A3 WO2014004863 A3 WO 2014004863A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
diseases
compositions
syndrome
sle
Prior art date
Application number
PCT/US2013/048243
Other languages
French (fr)
Other versions
WO2014004863A2 (en
Inventor
Paul R. Sebahar
Robert J. Halter
Donald A. Mcleod
Daniel P. Parker
Kraig M. Yager
Mark D. Shenderovich
Ryan C. Holcomb
Burt Richards
Paul L. Bartel
Se-Ho Kim
Paul M. Slattum
Rajendra Tangallapally
Richard Trovato
Ashantai J. Yungai
Original Assignee
Alzheimer's Institute Of America, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzheimer's Institute Of America, Inc. filed Critical Alzheimer's Institute Of America, Inc.
Publication of WO2014004863A2 publication Critical patent/WO2014004863A2/en
Publication of WO2014004863A3 publication Critical patent/WO2014004863A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to compounds, pharmaceutical compositions and medicaments comprising such compounds, and the use of these compounds, compositions, and medicaments in methods of treating a variety of diseases and disorders. The present invention provides compounds that inhibit IKK-related kinase epsilon, TANK-binding kinase 1 (TBKI), or both. These compounds may be used in the treatment of inflammation, RA, SLE, diseases associated with aberrant accumulation of cytosolic nucleic acids (including Sjogrens syndrome, Aicardi-Goutieres syndrome, subtypes of SLE, chilblain lupus, and RVCL), systemic sclerosis, myositis (including dermatomyositis and polymyositis), psoriasis, COPD, IBD, obesity, insulin resistance, NIDDM, metabolic syndrome and cancer, and complications associated with these diseases and disorders.
PCT/US2013/048243 2012-06-27 2013-06-27 Compounds, compositions, and therapeutic uses thereof WO2014004863A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261665270P 2012-06-27 2012-06-27
US61/665,270 2012-06-27

Publications (2)

Publication Number Publication Date
WO2014004863A2 WO2014004863A2 (en) 2014-01-03
WO2014004863A3 true WO2014004863A3 (en) 2014-04-03

Family

ID=49784020

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/048243 WO2014004863A2 (en) 2012-06-27 2013-06-27 Compounds, compositions, and therapeutic uses thereof

Country Status (1)

Country Link
WO (1) WO2014004863A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014006554A1 (en) * 2012-07-03 2014-01-09 Aurigene Discovery Technologies Limited 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
US20150183781A1 (en) * 2012-08-07 2015-07-02 Um Pharmauji Sdn. Bhd. 5-(1H-Pyrazol-4-yl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors
CA2922230A1 (en) 2013-08-30 2015-03-05 Ambit Biosciences Corporation Biaryl acetamide compounds and methods of use thereof
US9598424B2 (en) 2014-03-06 2017-03-21 Takeda Pharmaceutical Company Limited Heteroarylamide inhibitors of TBK1
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
ES2727376T3 (en) 2014-09-26 2019-10-15 Gilead Sciences Inc Aminotriazine derivatives useful as TANK binding kinase inhibitor compounds
JP6986972B2 (en) 2015-06-18 2021-12-22 エイティナイン バイオ リミテッド Substituted 4-benzyl and 4-benzoylpiperidin derivatives
JP6999424B2 (en) 2015-06-18 2022-01-18 エイティナイン バイオ リミテッド 1,4-substituted piperidine derivative
EP3313834A1 (en) * 2015-06-29 2018-05-02 Merck Patent GmbH Tbk/ikk inhibitor compounds and uses thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
BR122022024925B1 (en) 2015-10-16 2023-11-28 Abbvie Inc PROLONGED-RELEASE PHARMACEUTICAL COMPOSITION COMPRISING (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A]PYRROL[2,3-E]PYRAZIN-8-IL)-N-(2,2 ,2-TRIFLUOROETHYL) PYRROLI-DINE-1-CARBOXAMIDE
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN108430993A (en) 2015-12-17 2018-08-21 吉利德科学公司 TANK- combination kinase inhibitor compounds
WO2017102091A1 (en) 2015-12-18 2017-06-22 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
WO2019169306A1 (en) * 2018-03-01 2019-09-06 The Trustees Of Columbia University In The City Of New York Compounds, compositions, and methods for suppressing toxic endoplasmic reticulum stress
WO2020170205A1 (en) 2019-02-22 2020-08-27 1ST Biotherapeutics, Inc. Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
EP4262788A1 (en) * 2020-12-16 2023-10-25 Merck Sharp & Dohme LLC Urea orexin receptor agonists
WO2022243649A1 (en) * 2021-05-21 2022-11-24 Centre National De La Recherche Scientifique (Cnrs) Novel azaindole derivatives as anticancer agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060122185A1 (en) * 2004-11-22 2006-06-08 Jeremy Green Bicyclic inhibitors of Rho kinase
US20060270646A1 (en) * 2003-03-06 2006-11-30 Eisai Co., Ltd. Jnk inhibitors
US20090233955A1 (en) * 2004-12-08 2009-09-17 Frazee James S 1H-Pyrrolo[2,3-B]Pyridnes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270646A1 (en) * 2003-03-06 2006-11-30 Eisai Co., Ltd. Jnk inhibitors
US20060122185A1 (en) * 2004-11-22 2006-06-08 Jeremy Green Bicyclic inhibitors of Rho kinase
US20110081364A1 (en) * 2004-11-22 2011-04-07 Hayley Binch Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
US20090233955A1 (en) * 2004-12-08 2009-09-17 Frazee James S 1H-Pyrrolo[2,3-B]Pyridnes

Also Published As

Publication number Publication date
WO2014004863A2 (en) 2014-01-03

Similar Documents

Publication Publication Date Title
WO2014004863A3 (en) Compounds, compositions, and therapeutic uses thereof
NZ599826A (en) Amino-pyrimidine compounds as inhibitors of ikk epsilon and/or tbk1
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
SG10201903475TA (en) New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
AU2012277802A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
WO2014144130A3 (en) Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof
WO2015077503A8 (en) Autotaxin inhibitor compounds
SG11201900460RA (en) Substituted diazahetero-bicyclic compounds and their use
WO2008074997A8 (en) Pyridine benzamides and pyrazine benzamides used as pkd inhibitors
WO2015013635A3 (en) Inhibitors of transcription factors and uses thereof
IL202158A (en) Oxadiazole derivatives, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments for the treatment of neurological and psychiatric disorders
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
WO2013013815A8 (en) Substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
EP2853543A8 (en) Anti-blys antibody
WO2015200790A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
MX2012007548A (en) Thieno [2,3-b] pyridinedione activators of ampk and therapeutic uses thereof.
WO2014058979A8 (en) Laquinimod for reducing thalamic damage in multiple sclerosis
NZ717504A (en) Methods of treatment of cancer by continuous infusion of coenzyme q10
MX2021010041A (en) Pharmaceutical compositions comprising akt protein kinase inhibitors.
MX2017008083A (en) 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-ami ne compound inhibitors of beta-secretase.
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
BR112014018657A8 (en) 1H-INDAZOL-3-CARBOXAMIDE COMPOUNDS
WO2013087654A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13810271

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2015520516

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 13810271

Country of ref document: EP

Kind code of ref document: A2